ArticleNature2021
Using DNA sequencing data to quantify T cell fraction and therapy response.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
5.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 73 citations in OpenAlex.
- Integrative Multi-Omics and Experimental Validation Define RELB as an Immune-Related Prognostic Driver in Ovarian Cancer.Chemical biology & drug design · 2026Article
- Aristolochic Acid and Alternative Lengthening of Telomeres Mechanisms Underlie Liver Angiosarcoma Pathogenesis.Liver cancer · 2026Article
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing.Molecular cancer research : MCR · 2026Article
- Article
- Comprehensive analysis of microbial content in whole-genome sequencing samples from The Cancer Genome Atlas project.Science translational medicine · 2025Article
- Low T cell diversity associates with poor outcome in bladder cancer: A comprehensive longitudinal analysis of the T cell receptor repertoire.Cell reports. Medicine · 2025Article
- ImmuneLENS characterizes systemic immune dysregulation in aging and cancer.Nature genetics · 2025Article
- Comprehensive genomic characterization of early-stage bladder cancer.Nature genetics · 2025Article
- Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade.Cancer immunology research · 2024Article
- Biomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review).Oncology letters · 2024Review
- Origins and impact of extrachromosomal DNA.Nature · 2024Article
- Mosaic chromosomal alterations in hematopoietic cells and clinical outcomes in patients with multiple myeloma.Leukemia · 2024Article
- MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution.Nature genetics · 2024Article
- Exploring the molecular landscape of cancer of unknown primary: A comparative analysis with other metastatic cancers.Molecular oncology · 2024Article
- Genetic determinants and phenotypic consequences of blood T-cell proportions in 207,000 diverse individuals.Nature communications · 2024Article
- Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma.Nature communications · 2024Article
- Deep cell phenotyping and spatial analysis of multiplexed imaging with TRACERx-PHLEX.Nature communications · 2024Article
- Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models.Nature communications · 2024Article
- Genetic landscape of interval and screen detected breast cancer.NPJ precision oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 20 institutions in 9 countries.
Robert Bentham *Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Kevin Litchfield *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Thomas B K Watkins *Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Emilia L LimCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Rachel RosenthalCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Carlos Martínez-RuizCancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Crispin T HileyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Maise Al BakirCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Roberto SalgadoDepartment of Pathology, GZA-ZNA, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-1110-3801
David A MooreCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-1212-1259
TRACERx Consortium
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-4299-3018
Nicholas McGranahanCancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.ORCID http://orcid.org/0000-0001-9537-4045
London Cancer · GBThe Francis Crick Institute · GBRoyal London Hospital · GBCancer Research UK · GBRoyal Brompton & Harefield NHS Foundation Trust · GBManchester University NHS Foundation Trust · GBSheffield Teaching Hospitals NHS Foundation Trust · GBAberdeen Royal Infirmary · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity Hospitals of Leicester NHS Trust · GBUniversity of Leicester · GBUniversity Hospital Southampton NHS Foundation Trust · GBCancer Research UK Manchester CentreGolden Jubilee National Hospital · GBBarts Health NHS Trust · GBCardiff and Vale University Health Board · GBPrincess Alexandra Hospital NHS Trust · GBThe Christie NHS Foundation Trust · GBMax Delbrück Center · DENHS Greater Glasgow and Clyde · GB
Funding
Cancer Research UK 17786Cancer Research UK 19278Cancer Research UK 20466Cancer Research UK 24956Cancer Research UK 25223Cancer Research UK 25253Cancer Research UK 30025Cancer Research UK 30194Medical Research Council MR/L016311/1Medical Research Council MR/P014712/1Medical Research Council MR/V033077/1Wellcome Trust 211179/Z/18/Z
Abstract
The immune microenvironment influences tumour evolution and can be both prognostic and predict response to immunotherapy
Indexed as
ImmunotherapyAdenocarcinoma of LungAspartic Acid EndopeptidasesCohort StudiesExomeExome SequencingFemaleHumansLymphocytes, Tumor-InfiltratingMaleMutationNeoplasmsPrognosisReceptors, Antigen, T-Cell, alpha-betaT-LymphocytesAspartic Acid EndopeptidasesReceptors, Antigen, T-Cell, alpha-betasignal peptide peptidase like 3, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.